Canakinumab treatment for patients with active recurrent or chronic TRAPS: an open-label, phase II study
Gattorno M, Obici L, et al.
Ann Rheum Dis · 2017
Key Findings
- ●Phase II proof-of-concept: 20 patients treated with canakinumab 150mg q4w
- ●Demonstrated efficacy and safety in TRAPS
Referenced in (1 disease)
Validation history
Full log →No validation events recorded yet. Source will be checked on the next kipine-source-validator run.
ID: pmid-27269295DOI: 10.1136/annrheumdis-2015-209031PMID: 27269295